fasudil has been researched along with Allergic Encephalomyelitis in 18 studies
fasudil: intracellular calcium antagonist; structure in first source
fasudil : An isoquinoline substituted by a (1,4-diazepan-1-yl)sulfonyl group at position 5. It is a Rho-kinase inhibitor and its hydrochloride hydrate form is approved for the treatment of cerebral vasospasm and cerebral ischemia.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Fasudil has been confirmed to improve experimental autoimmune encephalomyelitis (EAE), an animal model of MS." | 1.91 | Hydroxyfasudil regulates immune balance and suppresses inflammatory responses in the treatment of experimental autoimmune encephalomyelitis. ( Chu, GG; Ding, ZB; Huang, JJ; Ma, CG; Song, LJ; Wang, J; Wang, Q; Xiao, BG; Yin, JZ, 2023) |
| "But Fasudil-treated MNCs did not trigger EAE development." | 1.43 | [Immunoregulative effect of Fasudil on encephalomyelitic T cells in experimental autoimmune encephalomyelitis mice]. ( Guo, S; Liu, C; Ma, C; Xiao, B; Yu, J; Zhang, N, 2016) |
| " In the current study, we observed the therapeutic potential of MSCs combined with Fasudil in mouse model of experimental autoimmune encephalomyelitis (EAE) and explored possible mechanisms of action." | 1.43 | Synergistic and Superimposed Effect of Bone Marrow-Derived Mesenchymal Stem Cells Combined with Fasudil in Experimental Autoimmune Encephalomyelitis. ( Li, YH; Liu, CY; Liu, JC; Ma, CG; Song, GB; Wang, Q; Xiao, BG; Yan, YP; Yang, WF; Yu, JW; Yu, JZ; Zhang, HF, 2016) |
| "The treatment of Fasudil shifted inflammatory M1 to anti-inflammatory M2 macrophages in both early and late treatment, being shown by inhibiting CD16/32, iNOS, IL-12, TLR4 and CD40 and increasing CD206, Arg-1, IL-10 and CD14 in spleen." | 1.39 | Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil. ( Feng, L; Guo, M; Hou, S; Li, Y; Liu, C; Liu, Y; Ma, C; Meng, J; Xiao, B; Xie, Y; Yu, J; Zhang, H, 2013) |
| "Fasudil ameliorates disease progression in EAE, acting possibly through antiinflammatory pathway." | 1.38 | Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect. ( Feng, L; Guo, MF; Hou, SW; Li, YH; Liu, CY; Liu, YT; Ma, CG; Meng, J; Xiao, BG; Xie, Y; Yu, JZ; Zhang, HF, 2012) |
| "Fasudil was injected on day 3 p." | 1.38 | [Effect of Fasudil on miroglia and astrocytes in experimental autoimmune encephalomyelitis mice]. ( Feng, L; Ji, N; Li, YH; Liu, CY; Ma, CG; Xiao, BG; Yan, YY; Yu, JZ; Zhang, HF; Zhang, PJ, 2012) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (5.56) | 29.6817 |
| 2010's | 16 (88.89) | 24.3611 |
| 2020's | 1 (5.56) | 2.80 |
| Authors | Studies |
|---|---|
| Chu, GG | 1 |
| Wang, J | 1 |
| Ding, ZB | 2 |
| Yin, JZ | 1 |
| Song, LJ | 1 |
| Wang, Q | 3 |
| Huang, JJ | 1 |
| Xiao, BG | 13 |
| Ma, CG | 14 |
| Yan, Y | 1 |
| Yu, J | 4 |
| Gao, Y | 1 |
| Kumar, G | 1 |
| Guo, M | 2 |
| Zhao, Y | 1 |
| Fang, Q | 1 |
| Zhang, H | 4 |
| Jiang, Y | 1 |
| Zhang, HT | 1 |
| Guo, SD | 2 |
| Liu, CY | 8 |
| Yu, JW | 2 |
| Chai, Z | 3 |
| Mi, XT | 1 |
| Song, GB | 2 |
| Li, YH | 10 |
| Yang, PW | 1 |
| Feng, L | 8 |
| Liu, C | 2 |
| Li, Y | 1 |
| Hou, S | 1 |
| Liu, Y | 1 |
| Xie, Y | 2 |
| Meng, J | 4 |
| Xiao, B | 2 |
| Ma, C | 2 |
| Guo, MF | 2 |
| Yu, JZ | 11 |
| Yang, WF | 4 |
| Li, JL | 1 |
| Feng, QJ | 2 |
| Zhao, YF | 4 |
| Zhang, X | 1 |
| Yang, XW | 1 |
| Zhang, Q | 4 |
| Zhang, HZ | 2 |
| Chen, C | 3 |
| Yuan, HJ | 1 |
| Xin, YL | 1 |
| Liu, JC | 2 |
| Zhang, GX | 1 |
| Zhang, HF | 4 |
| Guo, S | 1 |
| Zhang, N | 1 |
| Yan, YP | 1 |
| Ding, J | 1 |
| Sun, CH | 1 |
| Sun, YF | 1 |
| Lu, CZ | 1 |
| Huang, XN | 1 |
| Fu, J | 1 |
| Wang, WZ | 1 |
| Hou, SW | 1 |
| Liu, YT | 1 |
| Zhang, PJ | 1 |
| Ji, N | 1 |
| Yan, YY | 1 |
| Sun, X | 1 |
| Minohara, M | 1 |
| Kikuchi, H | 1 |
| Ishizu, T | 1 |
| Tanaka, M | 1 |
| Piao, H | 1 |
| Osoegawa, M | 1 |
| Ohyagi, Y | 1 |
| Shimokawa, H | 1 |
| Kira, J | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Pilot Study of Telmisartan (Micardis) For the Prevention of Acute Graft vs. Host Disease Post Allogeneic Hematopoietic Stem Cell Transplantation[NCT02338232] | 32 participants (Actual) | Interventional | 2015-07-07 | Terminated (stopped due to Lack of Accrual) | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for fasudil and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Therapeutic potentials of the Rho kinase inhibitor Fasudil in experimental autoimmune encephalomyelitis and the related mechanisms.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cytokines; Encephalomyelitis, Autoimmune, Ex | 2019 |
17 other studies available for fasudil and Allergic Encephalomyelitis
| Article | Year |
|---|---|
Hydroxyfasudil regulates immune balance and suppresses inflammatory responses in the treatment of experimental autoimmune encephalomyelitis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Encephalomyelitis, Autoimmune, Experimental; | 2023 |
Nasal delivery of Fasudil-modified immune cells exhibits therapeutic potential in experimental autoimmune encephalomyelitis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Administration, Intranasal; Animals; Cell- and Tissue | 2019 |
Targeting the shift from M1 to M2 macrophages in experimental autoimmune encephalomyelitis mice treated with fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Encephalomyelitis, Autoimmune, Experimental; | 2013 |
The inhibition of Rho kinase blocks cell migration and accumulation possibly by challenging inflammatory cytokines and chemokines on astrocytes.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Animals, Newborn; Astrocytes; CD4-Positive T | 2014 |
The therapeutic potential of Rho kinase inhibitor fasudil derivative FaD-1 in experimental autoimmune encephalomyelitis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Cells, Cultured; Encephalomyelitis, Autoimmu | 2015 |
Fasudil regulates T cell responses through polarization of BV-2 cells in mice experimental autoimmune encephalomyelitis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Anti-Inflammatory Agents; Cell Line; Cell Pr | 2014 |
Fasudil mediates cell therapy of EAE by immunomodulating encephalomyelitic T cells and macrophages.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Arginase; Cell- and Tissue-Based Therapy; Ch | 2015 |
Protective effect of a novel Rho kinase inhibitor WAR-5 in experimental autoimmune encephalomyelitis by modulating inflammatory response and neurotrophic factors.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amides; Aminopyridines; Animals; Cytokines; Encephalo | 2015 |
Role of Rho Kinase and Fasudil on Synaptic Plasticity in Multiple Sclerosis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Adolescent; Adult; Animals; Cells, Cultured; Central | 2015 |
Changes of synapses in experimental autoimmune encephalomyelitis by using Fasudil.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blotting, Western; Cells, Cultured; Cytokine | 2016 |
[Immunoregulative effect of Fasudil on encephalomyelitic T cells in experimental autoimmune encephalomyelitis mice].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Encephalomyelitis, Autoimmune, Experimental; | 2016 |
Synergistic and Superimposed Effect of Bone Marrow-Derived Mesenchymal Stem Cells Combined with Fasudil in Experimental Autoimmune Encephalomyelitis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Bone Marrow Cells; Brain-Derived Neurotrophi | 2016 |
Therapeutic potential of experimental autoimmune encephalomyelitis by Fasudil, a Rho kinase inhibitor.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Analysis of Variance; Animals; Cell Proliferation; Ce | 2010 |
The effects of fasudil on the permeability of the rat blood-brain barrier and blood-spinal cord barrier following experimental autoimmune encephalomyelitis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Blood-Brain Barrier; Cell Membrane Permeabil | 2011 |
Fasudil ameliorates disease progression in experimental autoimmune encephalomyelitis, acting possibly through antiinflammatory effect.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Amino Acid Sequence; Animals; Anti-Inflammatory Agent | 2012 |
[Effect of Fasudil on miroglia and astrocytes in experimental autoimmune encephalomyelitis mice].
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Astrocytes; Encephalomyelitis, Autoimmune, E | 2012 |
The selective Rho-kinase inhibitor Fasudil is protective and therapeutic in experimental autoimmune encephalomyelitis.
Topics: 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine; Animals; Central Nervous System; Chemotaxis, Leukocyt | 2006 |